Grifols (GIFLF) Non-Current Deferred Tax Liability (2009 - 2025)
Grifols' (GIFLF) quarterly Non-Current Deferred Tax Liability came in at $1.0 billion in Q4 2025, down 7.32% on a YoY basis from $1.1 billion in Q4 2024, and down 7.32% quarter-over-quarter from $1.1 billion in Q4 2024.
Analysis
Grifols (GIFLF) Non-Current Deferred Tax Liability (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Non-Current Deferred Tax Liability for 17 consecutive years, with $1.0 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deferred Tax Liability fell 7.32% year-over-year to $1.0 billion; the trailing twelve-month figure through Dec 2025 stood at $1.0 billion (down 7.32% YoY), and the FY2025 full-year result was $972.8 million, down 10.05% from the prior year.
- Non-Current Deferred Tax Liability slipped to $1.0 billion in Q4 2025 per GIFLF's latest filing, from $1.1 billion in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.1 billion in Q4 2024 and bottomed at $725.3 million in Q4 2021.
- Historically, Non-Current Deferred Tax Liability has averaged $985.7 million across 5 years, with a median of $1.1 billion in 2022.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deferred Tax Liability jumped 45.57% in 2022, then slipped 7.32% in 2025.
- Over 5 years, Non-Current Deferred Tax Liability stood at $725.3 million in 2021, then jumped by 45.57% to $1.1 billion in 2022, then climbed by 0.75% to $1.1 billion in 2023, then grew by 1.67% to $1.1 billion in 2024, then retreated by 7.32% to $1.0 billion in 2025.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $1.0 billion, $1.1 billion, and $1.1 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.00 Bn |
| Dec 31, 2024 | 1.08 Bn |
| Dec 31, 2023 | 1.06 Bn |
| Dec 31, 2022 | 1.06 Bn |
| Dec 31, 2021 | 725.26 Mn |
| Dec 31, 2020 | 663.88 Mn |
| Dec 31, 2019 | 377.23 Mn |
| Dec 31, 2018 | 333.13 Mn |
| Jun 30, 2018 | 470.02 Mn |
| Dec 31, 2017 | 457.92 Mn |
| Jun 30, 2017 | 629.10 Mn |
| Dec 31, 2016 | 648.53 Mn |
| Sep 30, 2016 | 676.26 Mn |
| Jun 30, 2016 | 702.52 Mn |
| Dec 31, 2015 | 692.27 Mn |
| Sep 30, 2015 | 654.33 Mn |
| Jun 30, 2015 | 628,910.48 |
| Mar 31, 2015 | 673.10 Mn |
| Dec 31, 2014 | 673.39 Mn |
| Sep 30, 2014 | 704.28 Mn |